阿得巴司 | 791828-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 阿得巴司
• 中文别名: (6S,7s)-7-(羟基氨基甲酰)-6-(4-苯基哌嗪-1-羰基)-5-氮杂螺[2.5]辛烷-5-羧酸甲酯；(6S,7S)-7-[(羟基氨基)甲酰基]-6-[(4-苯基-1-哌嗪基)甲酰基]-5-氮杂螺[2.5]辛烷-5-甲酸甲酯；INCB7839；INCB007839
• 英文名称: methyl (6S,7S)-7-[(hydroxyamino)carbonyl]-6-[(4-phenylpiperazin-1-yl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylate
• 英文别名: Aderbasib；methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate
• CAS: 791828-58-5
• 化学式: C₂₁H₂₈N₄O₅
• 分子量: 416.477
• InChiKey: DJXMSZSZEIKLQZ-IRXDYDNUSA-N

物化性质

• 密度：
  1.38
• 溶解度：
  DMSO：100 mg/mL（240.11 mM；需要超声）

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  tert-butyl (6S,7S)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2,5)octane-7-carboxylate 在 N-甲基吗啉 、 盐酸羟胺 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 5.25h， 生成 阿得巴司
  参考文献：
  名称：

  AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES

  摘要：

  公开号：

  EP1622569B1

文献信息

• Aza spiro alkane derivatives as inhibitors of metalloproteases
  申请人：——

  公开号：US20040259896A1

  公开（公告）日：2004-12-23

  The present invention provides a compound of Formula I or Formula II: 1 enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.

  本发明提供了公式I或公式II的化合物：1对映异构体，对映体，前药，溶剂化物，代谢物或其药学上可接受的盐，其中组分变量在此处提供。公式I和II的化合物是金属蛋白酶调节剂，可用于治疗与金属蛋白酶活性相关的疾病，如关节炎，癌症，心血管疾病，皮肤疾病，炎症和过敏症。
• AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES
  申请人：Yao Wenqing

  公开号：US20110288068A1

  公开（公告）日：2011-11-24

  The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.

  本发明提供了化合物I或化合物II的化合物：对映体、顺反异构体、前药、溶剂化物、代谢物或其药学上可接受的盐，其中组成变量在此处提供。化合物I和II是金属蛋白酶调节剂，可用于治疗与金属蛋白酶活性相关的疾病，如关节炎、癌症、心血管疾病、皮肤疾病、炎症和过敏症。
• AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases
  申请人：INCYTE CORPORATION

  公开号：US20140187530A1

  公开（公告）日：2014-07-03

  The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.

  本发明提供公式I或公式II的化合物：其对映体，顺反异构体，前药，溶剂化物，代谢物或其药学上可接受的盐，其中组成变量在此提供。公式I和II的化合物是金属蛋白酶调节剂，并且在治疗与金属蛋白酶活性相关的疾病，例如关节炎，癌症，心血管疾病，皮肤疾病，炎症和过敏症方面是有用的。
• SHEDDASE INHIBITORS COMBINED WITH CD30-BINDING IMMUNOTHERAPEUTICS FOR THE TREATMENT OF CD30 POSITIVE DISEASES
  申请人：Friedman Steven M.

  公开号：US20070280943A1

  公开（公告）日：2007-12-06

  The present invention is directed to pharmaceutical methods for the treatment of CD30 positive diseases, such as Hodgkin's disease, by administration of a combination of at least one sheddase inhibitor and at least one anti-CD30 immunotherapeutic.
• BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF
  申请人：INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY

  公开号：US20210010084A1

  公开（公告）日：2021-01-14

  The present invention provides MEL-18, which is a biomarker for human epidermal growth factor receptor2 (HER2)-positive cancer and anti-HER2 therapy, and a use thereof. According to the present invention, MEL-18 is a prognostic factor or predictor for a response of subjects to an anti-HER2-targeted drug in HER2-POSITIVE cancer and may be used in companion diagnostics for HER2-targeted drugs in subjects with HER2-positive cancer. Therefore, HER2-positive cancer may be more effectively treated by overcoming resistance to HER2 therapeutic agents and enhancing therapeutic efficacy by determining whether ADAM10/17 inhibitors are administered or co-administered with HER2-targeted drugs.